RxDoctor Payments Data

David Hadley, MD

Urology · Kettering, OHNPI 1225223043

Payments from drug & device makers

$2,557in general payments, 2019–2025

Across 27 payments — averaging $94.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Richard Wolf Medical Instruments Corp.$912
  • Procept Biorobotics Corporation$488
  • Astellas Pharma US Inc$328
  • Olympus America Inc.$249
  • Vertex$139
  • Boston Scientific$116
  • plus $324 from 8 others

What the payments were for

  • Travel & lodging$91236%
  • Food & beverage$1,32752%
  • Education$31712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,557 in reported general payments places this provider in the 45th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$250,327
Medicare patients
591
Services billed
3,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron34$23,958
Methenamine Hippurate128$6,152
Fosfomycin Tromethamine13$2,068
Oxybutynin Chloride ErOxybutynin Chloride113$1,759
Finasteride153$1,508
Tamsulosin Hcl138$1,109
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst102$927
Estradiol13$656
NitrofurantoinNitrofurantoin Macrocrystal15$545
Oxybutynin Chloride33$528
Doxycycline Hyclate11$233
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim40$199
Tramadol Hcl135$163
Cephalexin21$130
Fluconazole17$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$328$23,95834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 485 urology providers in Ohio.

Other urology in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →